Seroatlas · Human Serome Atlas

SRGN

Serglycin

Also known as: PPG, PRG, PRG1, SRGN_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P10124
Gene: SRGN
Ensembl: ENSG00000122862
Chromosome: 10
Canonical length: 158 aa
Protein class: Plasma proteins, Predicted secreted proteins
Subcellular location: Golgi apparatus
Secretome location: Secreted to blood

OverviewNCBI Gene

This gene encodes a protein best known as a hematopoietic cell granule proteoglycan. Proteoglycans stored in the secretory granules of many hematopoietic cells also contain a protease-resistant peptide core, which may be important for neutralizing hydrolytic enzymes. This encoded protein was found to be associated with the macromolecular complex of granzymes and perforin, which may serve as a mediator of granule-mediated apoptosis. Two transcript variants, only one of them protein-coding, have been found for this gene. [provided by RefSeq, Jul 2010]

Canonical amino-acid sequenceUniProt

158 residues, UniProt reviewed canonical sequence.

>P10124|SRGN
     1  MMQKLLKCSR LVLALALILV LESSVQGYPT RRARYQWVRC NPDSNSANCL EEKGPMFELL
    61  PGESNKIPRL RTDLFPKTRI QDLNRIFPLS EDYSGSGFGS GSGSGSGSGS GFLTEMEQDY
   121  QLVDESDAFH DNLRSLDRNL PSDSQDLGQH GLEEDFML

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SRGN can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.63
Highest tissue expression: 7,642 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 7,642 nTPM
appendix: 755 nTPM
urinary bladder: 474 nTPM
lymph node: 409 nTPM
adipose tissue: 378 nTPM
spleen: 342 nTPM

Single-cell type

neutrophils: 24,235 nCPM
neutrophil progenitors: 8,530 nCPM
mast cells: 7,093 nCPM
monocyte progenitors: 5,947 nCPM
monocytes: 5,941 nCPM
cdc: 3,895 nCPM

Immune cell

neutrophil: 5,738 nTPM
eosinophil: 2,737 nTPM
basophil: 2,359 nTPM
total PBMC: 1,590 nTPM
classical monocyte: 1,106 nTPM
NK-cell: 965 nTPM

Brain region

cerebral cortex: 140 nTPM
medulla oblongata: 100 nTPM
white matter: 75 nTPM
choroid plexus: 73 nTPM
hypothalamus: 69 nTPM
thalamus: 65 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.76
gnomAD pLI: 0.7
gnomAD missense Z: 0.6
DepMap mean gene effect: -0.12
DepMap dependency class: selective

OntologyGO

Biological processes

apoptotic process
biomineral tissue development
granzyme-mediated programmed cell death signaling pathway
mast cell secretory granule organization
negative regulation of bone mineralization
negative regulation of cytokine production
protein processing
secretory granule organization
maintenance of granzyme B location in T cell secretory granule
maintenance of protease location in mast cell secretory granule
T cell secretory granule organization

Cellular components

Protein domainsUniProt · Pfam · InterPro

Serglycin
Serglycin

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SRGN as an antibody target. Whether an autoantibody or antibody against SRGN could matter depends on whether native SRGN is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SRGN is annotated as secreted, so native SRGN circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label SRGN as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...